DIRECT (DIabetes REsearCh on patient straTification) is a consortium looking at personalized medicine for type 2 diabetes. The aims of the consortium are to identify biomarkers that address current bottlenecks in diabetes drug development and to develop a stratified medicines approach to the treatment of type 2 diabetes with either existing or novel therapies.

The consortium consists of 25 European partners, with seven interrelated research work packages, covering phenotype generation and provision, data generation and analysis, validation and assay development and validation through prospective clinical trials.

Jane Kaye, Karen Melham and Harriet Teare are the HeLEX researchers working on this project, and will be responsible for identifying, addressing and resolving ethical, legal and regulatory issues that emerge as the scientific work programmes develop and to ensure the development of best practice. Part of this work will focus in particular on patient engagement.

The DIRECT project started in January 2012 and will run for 7 years. The project is supported by the Innovative Medicines Initiative (IMI), which is part of the EU Seventh Framework Programme (FP7).

The project partners are: 

Sanofi-Aventis Deutschland GmbH 
Eli Lilly and Company Ltd.
University of Dundee
University of Bath 
Consiglio Nazionale delle Ricerche 
Technical University of Denmark 
Eberhard Karls Universität Tübingen 
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH
Consorci Institut D`Investigacions Biomediques August Pi i Sunyer 
Imperial College London 
Kungliga Tekniska Högskolan 
University of Lille – CNRS 
Leiden University Medical Center 
University of Copenhagen 
University of Eastern Finland 
Lunds Universitet 
University of Newcastle upon Tyne 
University of Exeter 
University of Gèneve 
University of Oxford 
Universität Ulm 
VU University Medical Center Amsterdam 
Novo Nordisk A/S 
Lille University Hospital